Sunho Biologics (HKSE:02898) EBIT per Share : HK$-0.67 (TTM As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics EBIT per Share?

Sunho Biologics's EBIT per Share for the six months ended in Jun. 2024 was HK$-0.36. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.67.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Sunho Biologics's EBIT per Share or its related term are showing as below:

HKSE:02898's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.1
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Sunho Biologics's EBIT for the six months ended in Jun. 2024 was HK$-38.23 Mil.

Sunho Biologics EBIT per Share Historical Data

The historical data trend for Sunho Biologics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunho Biologics EBIT per Share Chart

Sunho Biologics Annual Data

Trend

Dec22

Dec23

Dec24

EBIT per Share

-0.33

-0.92

-0.65

Sunho Biologics Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24	Dec24
EBIT per Share	-	-0.43	-0.49	-0.36	-0.31

Sunho Biologics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Sunho Biologics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-144.389	/	156.667
=	-0.92

Sunho Biologics's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

	EBIT per Share		(Q: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-38.229	/	105.520
=	-0.36

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.67

Sunho Biologics (HKSE:02898) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Sunho Biologics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Sunho Biologics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunho Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN

Website

http://www.sunho-bio.com.cn

Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.

Executives

Sunho Fortune Investments Limited	2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited	2301 Trustee
Zhang Feng	2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited	2101 Beneficial owner

Sunho Biologics Headlines

No Headlines